Table 6.
The protection of the Bivalent/quadrivalent and the 9-valent HPV vaccines for cervical precancer lesions and cancers in Chinese population.
| Cervical lesions | hrHPV positive case | HPV16/18 | HPV16/18/31/33/45/52/58 | ||
|---|---|---|---|---|---|
| Positive case | Percentage | Positive case | Percentage | ||
| CIN2/3 | 3,773 | 1626 | 43.1 | 3245 | 86.0 |
| AIS | 57 | 47 | 82.5 | 49 | 86.0 |
| AIS+CIN2/3 | 87 | 72 | 82.8 | 79 | 90.8 |
| Summary | 3,917 | 1,745 | 44.5 | 3,373 | 86.1 |
| SCC | 778 | 535 | 68.8 | 684 | 87.9 |
| ADC | 111 | 71 | 64 | 75 | 67.6 |
| ADSQ | 101 | 76 | 75.2 | 91 | 90.1 |
| SNEC | 17 | 14 | 82.4 | 14 | 82.4 |
| Summary | 1,007 | 696 | 69.1 | 864 | 85.8 |
CIN2/3, cervical intraepithelial neoplasia 2/3; AIS, endocervical adenocarcinoma in situ; SCC, squamous cell carcinoma of cervix, ADC, invasive adenocarcinoma of endocervix; ADSQ, adenosquamous carcinoma of endocervix; SNEC, small cell neuroendocrine carcinoma of endocervix; hrHPV, high-risk human papillomavirus.
The bold font represented the total data of each item.